Drug Trial Radar · NCT02150967
A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma
Last checked: Nov 20, 2026Latest source record: Jul 3, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
143
Actual
Start
Jul 23, 2014
Primary completion
Mar 1, 2021
Study completion Feb 7, 2022
Sponsor
- Lead sponsor
- QED Therapeutics, a BridgeBio companyIndustry
- Sponsor type
- Industry
- Collaborators
- Helsinn Healthcare SA
- First posted
- May 30, 2014
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, open label, single arm phase II study evaluating BGJ398 (infigratinib) anti-tumor activity in advanced or metastatic cholangiocarcinoma patients with fibroblast growth factor receptor (FGFR) genetic alterations.
Conditions
- Advanced Cholangiocarcinoma
- FGFR2 Gene Mutation
Interventions
BGJ398 (infigratinib)Drug
Capsule for oral use
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Response Rate (ORR) as Assessed by Blinded Independent Central Imaging Review (BICR)Time frame: Analysis was conducted when all subjects in Cohort 1 had the opportunity to be followed for at least 10 months after their initial exposure to infigratinib. Data cutoff 01 March 2021.
Locations
37 sites in 11 countries. Site status is shown where the registry gives one.
QED Investigative Site
Phoenix, Arizona
QED Investigative Site
Los Angeles, California
QED Investigative Site
Los Angeles, California
QED Investigative Site
San Francisco, California
QED Investigative Site
Boston, Massachusetts
QED Investigative Site
Detroit, Michigan
QED Investigative Site
New York, New York
QED Investigative Site
New York, New York
QED Investigative Site
New York, New York
QED Investigative Site
Columbus, Ohio
QED Investigative Site
Houston, Texas
QED Investigative Site
Brussels, Belgium
QED Investigative Site
Leuven, Belgium
QED Investigative Site
Heidelberg, Germany
QED Investigative Site
Tübingen, Germany
QED Investigative Site
Cologne, North Rhine-Westphalia, Germany
QED Investigative Site
Ancona, AN, Italy
QED Investigative Site
Milan, MI, Italy
QED Investigative Site
Roma, RM, Italy
QED Investigative Site
Moscow, Russia
QED Investigative Site
Volzhskiy, Russia
QED Investigative Site
Singapore, Singapore
QED Investigative Site
Singapore, Singapore
QED Investigative Site
Seoul, Korea, South Korea
QED Investigative Site
Seoul, Korea, South Korea
QED Investigative Site
Barcelona, Spain
QED Investigative Site
Barcelona, Spain
QED Investigative Site
Madrid, Spain
QED Investigative Site
Zhunan, Taiwan
QED Investigative Site
Taipei, Taiwan ROC, Taiwan
QED Investigative Site
Bangkok, Thailand
QED Investigative Site
Bangkok, Thailand
QED Investigative Site
Khon Kaen, THA, Thailand
QED Investigative Site
Bebington, United Kingdom
QED Investigative Site
Birmingham, United Kingdom
QED Investigative Site
Manchester, United Kingdom
QED Investigative Site
Nottingham, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.